4WTK image
Entry Detail
PDB ID:
4WTK
Keywords:
Title:
CRYSTAL STRUCTURE OF HCV NS5B GENOTYPE 2A JFH-1 ISOLATE WITH S15G E86Q E87Q C223H V321I MUTATIONS IN COMPLEX WITH RNA TEMPLATE 5'-AGCC, RNA PRIMER 5'-PGG, MN2+, AND CDP
Biological Source:
PDB Version:
Deposition Date:
2014-10-30
Release Date:
2015-02-11
Method Details:
Experimental Method:
Resolution:
2.50 Å
R-Value Free:
0.22
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 65
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:RNA-directed RNA polymerase
Mutations:S2457G, E2528Q, E2529Q, C2665H, V2763I
Chain IDs:C (auth: A)
Chain Length:580
Number of Molecules:1
Biological Source:Hepatitis C virus JFH-1
Polymer Type:polyribonucleotide
Description:RNA PRIMER GG
Chain IDs:B (auth: P)
Chain Length:2
Number of Molecules:1
Biological Source:synthetic construct
Polymer Type:polyribonucleotide
Description:RNA TEMPLATE AGCC
Chain IDs:A (auth: T)
Chain Length:4
Number of Molecules:1
Biological Source:synthetic construct
Primary Citation
Structural basis for RNA replication by the hepatitis C virus polymerase.
Science 347 771 775 (2015)
PMID: 25678663 DOI: 10.1126/science.1259210

Abstact

Nucleotide analog inhibitors have shown clinical success in the treatment of hepatitis C virus (HCV) infection, despite an incomplete mechanistic understanding of NS5B, the viral RNA-dependent RNA polymerase. Here we study the details of HCV RNA replication by determining crystal structures of stalled polymerase ternary complexes with enzymes, RNA templates, RNA primers, incoming nucleotides, and catalytic metal ions during both primed initiation and elongation of RNA synthesis. Our analysis revealed that highly conserved active-site residues in NS5B position the primer for in-line attack on the incoming nucleotide. A β loop and a C-terminal membrane-anchoring linker occlude the active-site cavity in the apo state, retract in the primed initiation assembly to enforce replication of the HCV genome from the 3' terminus, and vacate the active-site cavity during elongation. We investigated the incorporation of nucleotide analog inhibitors, including the clinically active metabolite formed by sofosbuvir, to elucidate key molecular interactions in the active site.

Legend

Protein

Chemical

Disease

Primary Citation of related structures